US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

42.72

+1.072.57%

Volume:219.40K

Turnover:9.26M

Market Cap:318.26M

PE:- -

High:42.86

Open:41.64

Low:41.44

Close:41.65

52wk High:42.97

52wk Low:23.90

Shares:7.45M

Float Shares:7.45M

Volume Ratio:0.69

T/O Rate:2.94%

Dividend:0.28

Dividend Rate:0.66%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Teva announces FDA approval of Degevma as a biosimilar to Xgeva

Pfizer, Moderna Lose Bids to Escape Bayer US mRNA Patent Lawsuit

Incyte management to meet with Oppenheimer

Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says

MT Newswires Live

MiniMed Names Sheila Denton General Counsel, Corporate Secretary

Transcode Therapeutics reports updated results from Phase 1a TTX-MC138 trial

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

Mirum Rises on FDA Nod for Rare Bone Disorder Drug

MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001

Incyte Corporation : H.c. Wainwright Raises Target Price to $152 from $150

THOMSON REUTERS

Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M

Incyte, Mirum's Treatment of Rare Genetic Ossification Condition Approved by US FDA

MT Newswires Live

Incyte : JP Morgan Raises Target Price to $123 from $120

THOMSON REUTERS

Hutchmed initiates Phase Ia part of trial of HMPL-A830

EBR Systems advances FDA approval process for new WiSE manufacturing site

Incyte (INCY) Gets a Hold from Bernstein

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/IDNA/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":42.72,"timestamp":1791230400000,"preClose":41.65,"halted":0,"volume":219396,"delay":0,"changeRate":0.025690276110444187,"floatShares":7450000,"shares":7450000,"eps":0,"marketStatus":"Pre-Mkt","change":1.07,"latestTime":"10-06 05:53:40 EDT","open":41.64,"high":42.855,"low":41.44,"amount":9262746.200987998,"amplitude":0.033974,"askPrice":49.66,"askSize":100,"bidPrice":38.07,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791293400000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":42.72,"sharesOutstanding":5100000,"nav":41.483661,"aum":309297448.94,"dividendRate":0.006601,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":42.97,"preClose":42.72,"latestTime":"19:59 EDT","volume":2505,"amount":107179.02,"timestamp":1791244769975,"change":0.25,"changeRate":0.005852,"amplitude":0.005852},"volumeRatio":0.6860378810274388,"impliedVol":0.2456,"impliedVolPercentile":0.696},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":7450000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6860378810274388,"shares":7450000,"dividePrice":0.282,"high":42.855,"amplitude":0.033974,"preClose":41.65,"low":41.44,"week52Low":23.9,"pbRate":"--","week52High":42.97,"institutionHeld":0,"latestPrice":42.72,"eps":0,"divideRate":0.006601,"volume":219396,"delay":0,"ttmEps":0,"open":41.64,"prevYearClose":26.19,"prevWeekClose":41.65,"prevMonthClose":42.32,"prevQuarterClose":42.32,"fiveDayClose":41.79,"twentyDayClose":39.77,"sixtyDayClose":33.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671125702","title":"Teva announces FDA approval of Degevma as a biosimilar to Xgeva","url":"https://stock-news.laohu8.com/highlight/detail?id=2671125702","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671125702?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:05","pubTimestamp":1790625914,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceutical Industries announced that the FDA has approved Degevma as a biosimilar to Xgeva. Degevma is indicated for the prevention...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PINK","IEIH","RSPH","TEVA","IDNA","LABU","MRNX","GNMX","NVIB","BK4007","BK4559","TECB","BK4566","MEDI","LU2324357040.USD","FRTY","BK4596","SYNB","XLVX","PSCH","LU1983299246.USD","BK4585","BK4584","GDOC","IBB","BMED","BBP","LFSC","MRNY","BK4557","TBXU","IYH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671827252","title":"Pfizer, Moderna Lose Bids to Escape Bayer US mRNA Patent Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2671827252","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671827252?lang=en_us&edition=fundamental","pubTime":"2026-09-29 02:20","pubTimestamp":1790619619,"startTime":"0","endTime":"0","summary":"Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuitSept 28 (Reuters)-A federal judge in Delaware on Monday rejected PfizerPFE.N, BioNTech22UAy.DEand Moderna'sMRNA.Orequests to dismiss pat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nL6N45K0Z5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4592","BK4588","IE00BLSP4452.SGD","BK4534","BK4550","MRNX","LU0122379950.USD","LU0456855351.SGD","IE000M9KFDE8.USD","BAYZF","GNOM","BNTX","BK4007","SG9999013999.USD","SG9999003800.SGD","SG9999011175.SGD","BK4581","LU1894683264.USD","LU0234572021.USD","LU0985481810.HKD","LU1066051498.USD","SG9999002232.USD","BK4139","LU0225771236.USD","SGXZ57979304.SGD","BK4599","SG9999002224.SGD","LU0058720904.USD","BK4548","BK4585","BK4532","LU1894683348.USD","LU1057294990.SGD","LU1066053197.SGD","LU0868494617.USD","LU0321505439.SGD","LU1883839398.USD","BK4568","OZEM","LU0306806265.USD","IE00BLSP4239.USD","SG9999001176.USD","LU2596442595.SGD","BK4501","WDNA","IE0002270589.USD","IE00BBT3K403.USD","LU0306807586.USD","IE00B19Z3581.USD","BK4533","IE00B3T34201.USD","LU0289739699.SGD","LU0321505868.SGD","PFE","IE00B19Z3B42.SGD","LGHT","LU1023059063.AUD","LU0225284248.USD","MRNA","BK4535","SG9999001176.SGD","MRNY","LU0170899867.USD","BK4551","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671825252","title":"Incyte management to meet with Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2671825252","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671825252?lang=en_us&edition=fundamental","pubTime":"2026-09-29 02:10","pubTimestamp":1790619011,"startTime":"0","endTime":"0","summary":"Meeting to be held in New York on October 6 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving bre...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/incyte-management-to-meet-with-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/incyte-management-to-meet-with-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","IDNA","BK4532","INCY","BK4550","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670259517","title":"Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670259517","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670259517?lang=en_us&edition=fundamental","pubTime":"2026-09-28 23:58","pubTimestamp":1790611096,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) is expected to have a \"strong\" launch for its Rasonque drug in second-line pancreatic ductal adenocarcinoma patients, and in some first-line patients as well, UBS Securitie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BBH","CANC","IE0002141913.USD","IE00BJT1NW94.SGD","PTH","RVMD","IE0009354923.USD","IDNA","LU0889565916.HKD","IE0009355771.USD","LU0109394709.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4139","IE00BFTCPJ56.SGD","LU0320765992.SGD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670123062","title":"MiniMed Names Sheila Denton General Counsel, Corporate Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2670123062","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670123062?lang=en_us&edition=fundamental","pubTime":"2026-09-28 21:03","pubTimestamp":1790600613,"startTime":"0","endTime":"0","summary":"MiniMed names Sheila Denton general counsel, corporate secretaryMiniMed named Sheila Denton general counsel and corporate secretary, effective immediately.Denton most recently served as general counse","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDLbqXPnF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314106906.USD","LU2089283258.USD","LU2271345857.HKD","LU2023251221.USD","LU0158827781.USD","LU1291159041.SGD","LU2111349929.HKD","LU0211326839.USD","IE00BVYPNW00.USD","LU0976567544.SGD","BK4082","LU2112291526.USD","LU1989764664.SGD","BK4588","IE00BQXX3C00.GBP","IE00BVYPNV92.GBP","IE00B3T34201.USD","IE00BGHQF631.EUR","LU0496365809.HKD","IE00B3PB1722.GBP","LU0208291251.USD","MMED","BK4585","LU1983299246.USD","BK4139","BK4533","LU0072461881.USD","LU2089284900.SGD","LU0162691827.USD","LU0211331839.USD","IDNA","BK4532","IE00BFXG1179.USD","LU0158827948.USD","IE000M9KFDE8.USD","LU0211326755.USD","LU0320765489.SGD","LU1571399168.USD","INCY","LU0070302665.USD","LU0432979614.USD","IE00BDGV0183.EUR","BK4198","IE00B42XCP33.USD","LU1023059063.AUD","LU1244550221.USD","LU2089984988.USD","MDT","LU1116320737.USD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670204232","title":"Transcode Therapeutics reports updated results from Phase 1a TTX-MC138 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2670204232","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670204232?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:10","pubTimestamp":1790597436,"startTime":"0","endTime":"0","summary":"TransCode Therapeutics (RNAZ) announced updated clinical data from its Phase 1a clinical trial of TTX-MC138, its novel anti-miR-10b therapeutic can...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/transcode-therapeutics-reports-updated-results-from-phase-1a-ttx-mc138-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/transcode-therapeutics-reports-updated-results-from-phase-1a-ttx-mc138-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GDOC","IDNA","BK4007","RNAZ","NVIB","LENZ","BK4539","MEDX","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670523240","title":"Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2670523240","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670523240?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:00","pubTimestamp":1790596800,"startTime":"0","endTime":"0","summary":"Initial data expected in the first half of 2027LEXINGTON, Mass., Sept.  28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focus","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369820/0/en/keros-therapeutics-announces-the-first-patient-dosing-in-the-phase-2-clinical-trial-evaluating-rinvatercept-in-dmd.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","GDOC","BK4139","LENZ","BK4007","IDNA","NVIB","HYLG","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670324162","title":"4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME","url":"https://stock-news.laohu8.com/highlight/detail?id=2670324162","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670324162?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:00","pubTimestamp":1790596800,"startTime":"0","endTime":"0","summary":"4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet needFirst patients have been enrolled in 4SIGHT global Phase 3 trial (","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369825/0/en/4dmt-advances-4d-150-into-phase-3-for-second-large-market-retina-indication-with-initiation-of-4sight-in-dme.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMDY","DAMD","ILDR","BK4534","AMDW","IDNA","LU1852331112.SGD","CHPS","CNAV","WISE","HYLG","SOXY","SOXX","MEDX","LEGR","AMDS","LU2108987350.USD","USXF","AMUU","IE00BMPRXN33.USD","CHAT","AIQ","AMDG","TTEQ","AMDU","NVIB","TEK","SAMD0main","AMDC","AMDD","AMDL","FAI","AMD","IETC","SMHX","ARTY","GAMR","XNTK","CST","FTXL","LU0979878070.USD","WUGI","SMH","QQQA","AMYY","TRFK","PSI","BAI","AIS","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670234567","title":"U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2670234567","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670234567?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:30","pubTimestamp":1790595000,"startTime":"0","endTime":"0","summary":"NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORIN rapamycin has the potential to become the first FDA-ap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369784/0/en/u-s-food-and-drug-administration-awards-additional-funding-for-qtorin-rapamycin-for-the-treatment-of-microcystic-lymphatic-malformations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","IDNA","BK4585","BMED","BK4588","GDOC","LABU","HYLG","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670313732","title":"Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2670313732","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670313732?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:00","pubTimestamp":1790593200,"startTime":"0","endTime":"0","summary":"– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors – NEW HAVEN, Conn., Sept.  28, 2026 (GLOBE NEWSWIRE) -- Arvi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369737/0/en/arvinas-announces-first-patient-dosed-in-phase-1-2-clinical-trial-of-arv-6723-the-company-s-first-immuno-oncology-candidate.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","GDOC","IDNA","NVIB","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670313352","title":"Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2670313352","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670313352?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:00","pubTimestamp":1790593200,"startTime":"0","endTime":"0","summary":"–Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits –Independent Cleveland Clinic cardio","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369741/0/en/moleculin-announces-publication-of-peer-reviewed-cardiac-safety-analysis-of-annamycin-in-frontiers-in-cardiovascular-medicine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BMED","MEDX","GDOC","IDNA","HYLG","CSII","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670694239","title":"Mirum Rises on FDA Nod for Rare Bone Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2670694239","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670694239?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:46","pubTimestamp":1790592368,"startTime":"0","endTime":"0","summary":"BUZZ-Mirum rises on FDA nod for rare bone disorder drug** Shares of drugmaker Mirum PharmaceuticalsMIRM.Orise 2.8% to $92.25 premarket** The US FDAlate on Fridayapproved MIRM's drug Atebrioz to treat ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nL6N45K0L6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","INCY","BK4139","BK4550","BK4588","IDNA","BK4532","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670605236","title":"MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2670605236","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670605236?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:15","pubTimestamp":1790590507,"startTime":"0","endTime":"0","summary":"MediciNova (MNOV) announced the topline results from MN-001-NATG-202, a Phase 2 clinical trial evaluating MN-001 for the treatment of hypertriglyce...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicinova-reports-results-from-mn-001-natg-202-phase-2-trial-of-mn-001-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicinova-reports-results-from-mn-001-natg-202-phase-2-trial-of-mn-001-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","MNOV","BBC","NVIB","PSIL","HYLG","MEDX","BK4139","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670363292","title":"Incyte Corporation : H.c. Wainwright Raises Target Price to $152 from $150","url":"https://stock-news.laohu8.com/highlight/detail?id=2670363292","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670363292?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:13","pubTimestamp":1790590397,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nAZN4TMDB3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4139","IDNA","BK4532","INCY","BK4550","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670236928","title":"Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M","url":"https://stock-news.laohu8.com/highlight/detail?id=2670236928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670236928?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:10","pubTimestamp":1790590220,"startTime":"0","endTime":"0","summary":"With the completion of the Theravance Biopharma acquisition and the receipt of the U.S. FDA approval of Ziihera for first-line HER2-positive advanc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","TBPH","PINK","PSCH","MRNX","MRNY","IBB","TECB","RSPH","BK4588","GDOC","SYNB","IEIH","BMED","GNMX","MEDI","BK4585","IDNA","BBP","IYH","TBXU","FRTY","LABU","NVIB","BK4007","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670428776","title":"Incyte, Mirum's Treatment of Rare Genetic Ossification Condition Approved by US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2670428776","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670428776?lang=en_us&edition=fundamental","pubTime":"2026-09-28 16:25","pubTimestamp":1790583903,"startTime":"0","endTime":"0","summary":"Incyte  and Mirum Pharmaceuticals'  Atebrioz tablet has been approved by the US Food and Drug Administration to treat adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva, the companies said Friday.The disease is a very rare genetic disease in which bone forms in muscles, tendons, ligaments and other soft tissues, progressively restricting movements. The drug reduces the volume of new ossification, they said.The drug, developed by Incyte and licensed to Mirum Pharmaceuticals, is expected to be available in the US in November, the companies said.The FDA also granted Incyte a rare pediatric disease priority review voucher which can be used in a later application, the companies said.The European Union is also now reviewing a marketing authorization application for the drug, the companies said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","BK4139","BK4550","INCY","BK4532","MIRM","LABU","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670533285","title":"Incyte : JP Morgan Raises Target Price to $123 from $120","url":"https://stock-news.laohu8.com/highlight/detail?id=2670533285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670533285?lang=en_us&edition=fundamental","pubTime":"2026-09-28 12:21","pubTimestamp":1790569293,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nFWN45I076:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4139","IDNA","BK4585","BK4532","INCY","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670402037","title":"Hutchmed initiates Phase Ia part of trial of HMPL-A830","url":"https://stock-news.laohu8.com/highlight/detail?id=2670402037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670402037?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:45","pubTimestamp":1790556321,"startTime":"0","endTime":"0","summary":"Hutchmed (HCM) announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hutchmed-initiates-phase-ia-part-of-trial-of-hmpl-a830-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hutchmed-initiates-phase-ia-part-of-trial-of-hmpl-a830-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","NVIB","BK4007","HYLG","BK4531","HCM","GDOC","BK4588","BK4585","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670402990","title":"EBR Systems advances FDA approval process for new WiSE manufacturing site","url":"https://stock-news.laohu8.com/highlight/detail?id=2670402990","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670402990?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:08","pubTimestamp":1790554084,"startTime":"0","endTime":"0","summary":"The latest announcement is out from EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:EBR) ). EBR Systems, developer of the WiSE wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","GDOC","GNMX","MEDI","BK4585","BMED","EES","IBB","IYH","TECB","RSPH","MRNY","TBXU","SYNB","MRNX","XLVX","FRTY","BBP","IDNA","LFSC","LABU","BK4588","NVIB","PINK","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670471553","title":"Incyte (INCY) Gets a Hold from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2670471553","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670471553?lang=en_us&edition=fundamental","pubTime":"2026-09-26 20:16","pubTimestamp":1790424990,"startTime":"0","endTime":"0","summary":"Bernstein analyst Jeffrey Walch maintained a Hold rating on Incyte yesterday and set a price target of $104.00. The company’s shares closed yesterd...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/incyte-incy-gets-a-hold-from-bernstein-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/incyte-incy-gets-a-hold-from-bernstein-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","INCY","BK4585","IDNA","BK4550","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}